These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 30383881)

  • 1. Use of Buprenorphine to Treat Opioid Use Disorder.
    Bartholow LAM; Pope J
    J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of NPs in medication-assisted treatment for opioid use disorder.
    Cotton BP; Ferszt GG
    Nurse Pract; 2018 May; 43(5):8. PubMed ID: 29668514
    [No Abstract]   [Full Text] [Related]  

  • 3. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 4. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery Beyond Buprenorphine: Nurse-Led Group Therapy.
    Fogger SA; Lehmann K
    J Addict Nurs; 2017; 28(3):152-156. PubMed ID: 28863059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using buprenorphine to treat patients with opioid use disorder.
    Radi JK; Fogarty KJ; Lagerwey MD
    JAAPA; 2019 Oct; 32(10):30-35. PubMed ID: 31513035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
    Cisewski DH; Santos C; Koyfman A; Long B
    Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Number Needed to Prescribe - What Would It Take to Expand Access to Buprenorphine?
    Poorman E
    N Engl J Med; 2021 May; 384(19):1783-1784. PubMed ID: 33983689
    [No Abstract]   [Full Text] [Related]  

  • 10. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
    Breen CT; Fiellin DA
    J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CE: Acute Pain Management for People with Opioid Use Disorder.
    Broglio K; Matzo M
    Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential.
    Fox L; Nelson LS
    CNS Drugs; 2019 Dec; 33(12):1147-1154. PubMed ID: 31552608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007-2017.
    McBain RK; Dick A; Sorbero M; Stein BD
    Ann Intern Med; 2020 Apr; 172(7):504-506. PubMed ID: 31905379
    [No Abstract]   [Full Text] [Related]  

  • 18. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
    Chou R; Ballantyne J; Lembke A
    Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
    [No Abstract]   [Full Text] [Related]  

  • 19. Stigma associated with medication treatment for young adults with opioid use disorder: a case series.
    Hadland SE; Park TW; Bagley SM
    Addict Sci Clin Pract; 2018 May; 13(1):15. PubMed ID: 29730987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Legal Authority for Emergency Medical Services to Increase Access to Buprenorphine Treatment for Opioid Use Disorder.
    Davis CS; Carr DH; Glenn MJ; Samuels EA
    Ann Emerg Med; 2021 Jul; 78(1):102-108. PubMed ID: 33781607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.